A recent study that used live virus culture to assess how well four rapid antigen tests are able to detect COVID variants of concern, suggests that while these tests remain a useful tool for the detection of COVID infections, continuous assessment and updating is likely needed in the context of variants of concern.
The findings, gathered by scientists at the Harvard T.H. Chan School of Public Health and Beth Israel Deaconess Medical Center, is published in the Journal of Clinical Microbiology.
Slightly less accurate than the genetic tests administered by healthcare professionals, the rapid antigen tests’ ease-of-use allows the general public to monitor themselves for COVID infections at home and make timely decisions to help stop the spread. The home tests, however, were developed and granted federal authorization for use with the original SARS-CoV-2 viral strain that emerged late in 2019.
Since then, the virus has evolved countless times, and several viral variants of concern have emerged, including the highly infectious delta and omicron variants that swept across the United States last summer and winter respectively.
“Unlike the sensitive molecular tests that detect multiple SARS-CoV-2 genes, rapid antigen tests target a single viral protein,” says co-corresponding author James Kirby, MD, director of the Clinical Microbiology Laboratory at BIDMC. “As the pandemic continues, however, some hypothesize that the performance of available antigen test may vary among the COVID variants of concern.”
Using three strains of cultured live virus, the team assessed differences in the limits of detection (LoD)–the smallest amount of viral antigen detectable at 95% certainty–of four commercially available rapid antigen tests; the Binax, CareStart, GenBody and LumiraDx tests. The researchers found that all four tests were as sensitive to the Omicron variant, if not more, as they were to original SARS-CoV-2 viral strain, known as WA1.
Three tests, however, showed less sensitivity to the Delta strain, with only the CareStart demonstrating equal detection of all three strains.
“We expect that the observed loss in Delta sensitivity could have resulted in a 20 percent or more loss of detection in potentially infectious individuals – nevertheless, the most infectious individuals still should have been detected,” says Kirby, also a professor of pathology at Harvard Medical School. “However, our findings suggest that antigen test performance needs to be reevaluated for emerging variants to ensure they still meet the intended public health testing goals of the pandemic.”
Co-authors included first author Sydney Stanley and co-senior corresponding author Phyllis J. Kanki of Harvard T.H. Chan School of Public Health; Stefan Riedel, Sanjucta Dutta, Elisa Contreras, Cody J. Callahan, Annie Cheng and Ramy Arnaout of BIDMC; Donald J. Hamel and Ian D. Wolf of Harvard T.H. Chan School of Public Health.
The authors acknowledge Ginkgo Bioworks provided CareStart and GenBody SARS-CoV-2 antigen test kits and Abbott and LumiraDx provided their respective SARS-CoV-2 antigen test kits used in this study. For a complete list of disclosures, please see the full study published by Journal of Clinical Microbiology.
